logo-loader

CelSci updates Phase 3 clinical trial of Advanced Head and Neck Cancer treatment

Published: 15:59 02 May 2019 EDT

CEL-SCI Corporation (NYSE:CVM) CEO Geert Kersten sat down with Proactive Investors at the ThinkEquity Conference in New York. The Virginia-based biotech treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with its drug Multikine before they receive surgery, radiation and/or chemotherapy.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

22 minutes ago